Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Board Appointment

13 Sep 2012 07:00

RNS Number : 1296M
Revolymer PLC
13 September 2012
 



Revolymer plc

("Revolymer" or "the Group")

Dr Bryan C Dobson to Join the Board of Revolymer

 

Former Croda International Plc ("Croda") executive to become an Independent Non-Executive Director

 

Revolymer (AIM: REVO), the British polymer company developing products for a number of high value fast moving consumer goods ("FMCG") markets, is pleased to announce with immediate effect the appointment of Dr Bryan Crawford Dobson to the Board of Directors as an independent non-executive director. Dr Dobson will also chair the Remuneration Committee.

 

Dr Dobson has 33 years' experience in the chemicals industry; 28 years with ICI and 5 years with Croda, and was most recently President Global Operations for Croda. He was a member of the executive management teams in Croda and in a number of large speciality chemicals businesses in ICI and has extensive management experience running regional and global business units in the UK, US, Belgium and The Netherlands. He also has expertise in developing new business in speciality chemicals sectors; extensive functional experience in R&D and operations and significant M&A experience.

 

Dr Dobson, commenting on his appointment said, "I am excited to be joining the Board of Revolymer and look forward to playing an active role in assisting the commercial and technical development of the Group, which has an attractive technology portfolio."

 

Jack Keenan, Chairman of Revolymer commenting on today's announcement said, "Bryan's decision to join the Board of Revolymer is yet another endorsement of the Group's technology and commercial strategy. His commercial and technical knowledge and expertise in both chemicals and FMCG markets complements well the skill base around the board table and will be instrumental in the further development of the Group's business."

 

Dr Dobson (aged 59) holds or has held the following directorships within the last 5 years:

 

Current

Previous

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Uniqema Nederland BV

Durham Graphene Science Ltd

 

 

Save as set out above, there is no information specified by paragraph (g) in Schedule Two to the AIM Rules that is required to be disclosed.

 

Ends

 

For further information please contact:

 

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

 

Citigate Dewe Rogerson

+44 (0)20 7638 9571

Simon Rigby / David Dible / Ginny Pulbrook

 

 

 

About Revolymer

Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. Current applications for the Group's technologies are in the confectionery chewing gum and medicated chewing gum (together "gum") markets; and in coatings & adhesives, household products and personal care (together "consumer specialties").

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALTMITMBTBBTT
Date   Source Headline
2nd Jun 20267:00 amRNSMello 2026 Presentation and Update on Trading
1st Jun 20267:00 amRNS-RProgress in Crop Production Field Trials
29th May 20267:00 amRNS-RDevelopment of Next Generation Plant-Based Paints
27th May 20267:00 amRNS-RLaunch of New Marketing Program for Detergents
14th May 20265:55 pmRNSAdjournment of AGM
6th May 20264:46 pmRNSDirector/PDMR Shareholding
27th Apr 20266:16 pmRNSTR-1
23rd Apr 20267:00 amRNSGrants of Options & PDMR dealings
24th Mar 20267:00 amRNSPreliminary Results
28th Jan 20267:00 amRNSTR-1
16th Jan 20265:29 pmRNSDirector/PDMR Shareholding
13th Jan 20267:00 amRNSFull Year Trading Update
15th Sep 20257:00 amRNSHalf Year Results
4th Sep 20257:00 amRNSNotice of Interim Results
27th Aug 20258:19 amRNSTR-1
23rd Jul 20257:00 amRNSH1 2025 Trading Update
16th Jul 20257:00 amRNS-RCroda expands agreement: sustainable odour control
1st Jul 20257:00 amRNS-RCommercial Plant-Based Product Launch
8th May 20252:20 pmRNSResult of AGM
6th May 202512:24 pmRNSTR-1
2nd May 20255:28 pmRNSNotice of AGM
1st May 20257:00 amRNSUpdate on US Tariffs
7th Apr 20257:00 amRNSGrants of Options & PDMR dealings
31st Mar 20257:00 amRNSPreliminary Results
18th Mar 20257:00 amRNSNotice of Results and Company Presentation
22nd Jan 20257:00 amRNSTrading Update
5th Nov 20247:00 amRNSTrading Update
10th Oct 20247:00 amRNSChange of Auditor
10th Sep 20247:00 amRNSHalf Year Results
2nd Sep 20247:00 amRNSNotice of Interim Results, Investor Presentation
16th Jul 20247:00 amRNSH1 2024 Trading Update
20th May 20243:03 pmRNSResult of AGM
20th May 20247:00 amRNSAGM Statement and Trading Update
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.